Journal article
Respiratory syncytial virus prophylaxis for children with chronic lung disease: have we got the criteria right?
Abstract
INTRODUCTION: The use of palivizumab for the prevention of respiratory syncytial virus-related hospitalization is well-established and has been adopted universally in pediatric position statements. Areas covered: The definition of chronic lung disease (CLD, bronchopulmonary dysplasia) has evolved over time and has significantly impacted the reported incidence of the condition, and the description of mild, moderate and severe disease in …
Authors
Paes B; Carbonell-Estrany X
Journal
Expert Review of Anti-infective Therapy, Vol. 17, No. 4, pp. 211–222
Publisher
Taylor & Francis
Publication Date
April 3, 2019
DOI
10.1080/14787210.2019.1581062
ISSN
1478-7210